Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsThe U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, citing unresolved issues found at a...
The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.
Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.
1.
When Healthcare Chatbots Fall Short of Human Connection
2.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
3.
Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening
4.
According to JAMA, even four minutes a day of exercise can lower the risk of cancer.
5.
Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.
1.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
2.
Comprehensive Standards in Oncology for Modern Medicine
3.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
4.
The Importance of Early Detection in Skin Cancer: Why Regular Skin Exams Matter
5.
Unveiling the Mystery Behind Lymphovascular Invasion
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation